Chiara Cerletti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4674007/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Exploring domains, clinical implications and environmental associations of a deep learning marker of biological ageing. European Journal of Epidemiology, 2022, 37, 35-48.	2.5	14
2	Fine-grained investigation of the relationship between human nutrition and global DNA methylation patterns. European Journal of Nutrition, 2022, 61, 1231-1243.	1.8	3
3	Psychological distress resulting from the COVID-19 confinement is associated with unhealthy dietary changes in two Italian population-based cohorts. European Journal of Nutrition, 2022, 61, 1491-1505.	1.8	12
4	Impact of Nationwide Lockdowns Resulting from the First Wave of the COVID-19 Pandemic on Food Intake, Eating Behaviors, and Diet Quality: A Systematic Review. Advances in Nutrition, 2022, 13, 388-423.	2.9	54
5	Mediterranean diet and other dietary patterns in association with biological aging in the Moli-sani Study cohort. Clinical Nutrition, 2022, 41, 1025-1033.	2.3	7
6	Association of Psychological Resilience with All-Cause and Cardiovascular Mortality in a General Population in Italy: Prospective Findings from the Moli-Sani Study. International Journal of Environmental Research and Public Health, 2022, 19, 222.	1.2	2
7	The night of randomized clinical trials where all patients are black: a need to estimate variability in treatment effects. , 2022, 1, 1-2.		1
8	Determinants of serum uric acid levels in an adult general population: results from the Moli-sani Study. Clinical Rheumatology, 2021, 40, 857-865.	1.0	1
9	Skin toxicity following radiotherapy in patients with breast carcinoma: is anthocyanin supplementation beneficial?. Clinical Nutrition, 2021, 40, 2068-2077.	2.3	9
10	The CASSIOPEA Study (Economic Crisis and Adherence to the Mediterranean diet: poSSIble impact on) Tj ETQqQ Rationale, design and characteristics of participants. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1053-1062.	0 0 rgBT 1.1	/Overlock 10 4
11	Ultra-processed food consumption is associated with increased risk of all-cause and cardiovascular mortality in the Moli-sani Study. American Journal of Clinical Nutrition, 2021, 113, 446-455.	2.2	103
12	Life-Course Socioeconomic Status and Risk of Hospitalization for Heart Failure or Atrial Fibrillation in the Moli-sani Study Cohort. American Journal of Epidemiology, 2021, 190, 1561-1571.	1.6	7
13	Changes in ultra-processed food consumption during the first Italian lockdown following the COVID-19 pandemic and major correlates: results from two population-based cohorts. Public Health Nutrition, 2021, 24, 3905-3915.	1.1	28
14	Changes in the consumption of foods characterising the Mediterranean dietary pattern and major correlates during the COVID-19 confinement in Italy: results from two cohort studies. International Journal of Food Sciences and Nutrition, 2021, 72, 1105-1117.	1.3	22
15	Dietary Polyphenol Intake Is Associated with Biological Aging, a Novel Predictor of Cardiovascular Disease: Cross-Sectional Findings from the Moli-Sani Study. Nutrients, 2021, 13, 1701.	1.7	12
16	Ultra-processed food consumption and its correlates among Italian children, adolescents and adults from the Italian Nutrition & Health Survey (INHES) cohort study. Public Health Nutrition, 2021, 24, 6258-6271.	1.1	27
17	Edible Mushrooms and Beta-Glucans: Impact on Human Health. Nutrients, 2021, 13, 2195.	1.7	57
18	Dietary selenium intake and risk of hospitalization for type 2 diabetes in the Moli-sani study cohort. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1738-1746.	1.1	25

#	Article	IF	CITATIONS
19	Genomic Overlap between Platelet Parameters Variability and Age at Onset of Parkinson Disease. Applied Sciences (Switzerland), 2021, 11, 6927.	1.3	4
20	Reduced pulmonary function, low-grade inflammation and increased risk of total and cardiovascular mortality in a general adult population: Prospective results from the Moli-sani study. Respiratory Medicine, 2021, 184, 106441.	1.3	12
21	Circulating Inflammation Markers Partly Explain the Link Between the Dietary Inflammatory Index and Depressive Symptoms. Journal of Inflammation Research, 2021, Volume 14, 4955-4968.	1.6	8
22	Dietary factors and the risk of lumbar spinal stenosis: a case–control analysis from the PREFACE Study. Nutrition, Metabolism and Cardiovascular Diseases, 2021, , .	1.1	1
23	NMU DNA methylation in blood is associated with metabolic and inflammatory indices: results from the Moli-sani study. Epigenetics, 2021, 16, 1-14.	1.3	4
24	Combined influence of depression severity and low-grade inflammation on incident hospitalization and mortality risk in Italian adults. Journal of Affective Disorders, 2021, 279, 173-182.	2.0	12
25	Association of a traditional Mediterranean diet and non-Mediterranean dietary scores with all-cause and cause-specific mortality: prospective findings from the Moli-sani Study. European Journal of Nutrition, 2021, 60, 729-746.	1.8	18
26	Daily Coffee Drinking Is Associated with Lower Risks of Cardiovascular and Total Mortality in a General Italian Population: Results from the Moli-sani Study. Journal of Nutrition, 2021, 151, 395-404.	1.3	15
27	Platelet Distribution Width Is Associated with P-Selectin Dependent Platelet Function: Results from the Moli-Family Cohort Study. Cells, 2021, 10, 2737.	1.8	16
28	Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Case–Cohort Study on Italian Women: Results from the Moli-sani Study. Thrombosis and Haemostasis, 2021, 121, 449-456.	1.8	5
29	Randomised trial of chronic supplementation with a nutraceutical mixture in subjects with non-alcoholic fatty liver disease. British Journal of Nutrition, 2020, 123, 190-197.	1.2	16
30	Assessing Genetic Overlap Between Platelet Parameters and Neurodegenerative Disorders. Frontiers in Immunology, 2020, 11, 02127.	2.2	10
31	Beyond Haemostasis and Thrombosis: Platelets in Depression and Its Co-Morbidities. International Journal of Molecular Sciences, 2020, 21, 8817.	1.8	32
32	Revisiting the link between platelets and depression through genetic epidemiology: new insights from platelet distribution width. Haematologica, 2020, 105, e246-e248.	1.7	17
33	Associations between systemic inflammation and somatic depressive symptoms: Findings from the Moliâ€sani study. Depression and Anxiety, 2020, 37, 935-943.	2.0	9
34	Socioeconomic and psychosocial determinants of adherence to the Mediterranean diet in a general adult Italian population. European Journal of Public Health, 2019, 29, 328-335.	0.1	37
35	Variation of PEAR1 DNA methylation influences platelet and leukocyte function. Clinical Epigenetics, 2019, 11, 151.	1.8	25
36	F48INVESTIGATING THE RELATION BETWEEN MENTAL HEALTH AND LOW GRADE INFLAMMATION. European Neuropsychopharmacology, 2019, 29, S1135.	0.3	0

#	Article	IF	CITATIONS
37	ZBTB12 DNA methylation is associated with coagulation- and inflammation-related blood cell parameters: findings from the Moli-family cohort. Clinical Epigenetics, 2019, 11, 74.	1.8	12
38	Socioeconomic trajectories across the life course and risk of total and cause-specific mortality: prospective findings from the Moli-sani Study. Journal of Epidemiology and Community Health, 2019, 73, 516-528.	2.0	7
39	Chili Pepper Consumption and Mortality in Italian Adults. Journal of the American College of Cardiology, 2019, 74, 3139-3149.	1.2	57
40	Interaction between Mediterranean diet and statins on mortality risk in patients with cardiovascular disease: Findings from the Moli-sani Study. International Journal of Cardiology, 2019, 276, 248-254.	0.8	19
41	Alcohol consumption and hospitalization burden in an adult Italian population: prospective results from the Moliâ€sani study. Addiction, 2019, 114, 636-650.	1.7	14
42	Abstract P079: Prediction of All-Cause Mortality in Diabetic Patients. Circulation, 2019, 139, .	1.6	0
43	Abstract P224: Chili Pepper Intake and Risk of Total and Cardiovascular Mortality in Italian Adults: Prospective Findings From the Moli-Sani Study. Circulation, 2019, 139, .	1.6	0
44	Association of proinflammatory diet with low-grade inflammation: results from the Moli-sani study. Nutrition, 2018, 54, 182-188.	1.1	66
45	Serum vitamin D deficiency and risk of hospitalization for heart failure: Prospective results from the Moli-sani study. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 298-307.	1.1	21
46	Reduced mortality risk by a polyphenol-rich diet: An analysis from the Moli-sani study. Nutrition, 2018, 48, 87-95.	1.1	31
47	Health-related quality of life and risk of composite coronary heart disease and cerebrovascular events in the Moli-sani study cohort. European Journal of Preventive Cardiology, 2018, 25, 287-297.	0.8	11
48	Age- and sex-based ranges of platelet count and cause-specific mortality risk in an adult general population: prospective findings from the Moli-sani study. Platelets, 2018, 29, 312-315.	1.1	15
49	Body Mass Index and Mortality in Elderly Subjects from the Moli-Sani Study: A Possible Mediation by Low-Grade Inflammation?. Immunological Investigations, 2018, 47, 774-789.	1.0	8
50	Socioeconomic status and impact of the economic crisis on dietary habits in Italy: results from the INHES study. Journal of Public Health, 2018, 40, 703-712.	1.0	15
51	Mediterranean diet and mortality in the elderly: a prospective cohort study and a meta-analysis. British Journal of Nutrition, 2018, 120, 841-854.	1.2	74
52	Mediterranean diet, dietary polyphenols and low grade inflammation: results from the MOLI ANI study. British Journal of Clinical Pharmacology, 2017, 83, 107-113.	1.1	164
53	Dietary anthocyanins and health: data from FLORA and ATHENA EU projects. British Journal of Clinical Pharmacology, 2017, 83, 103-106.	1.1	47
54	Relative contribution of health-related behaviours and chronic diseases to the socioeconomic patterning of low-grade inflammation. International Journal of Public Health, 2017, 62, 551-562.	1.0	28

#	Article	IF	CITATIONS
55	Pharmacogenomics of Antiplatelet Drugs. , 2017, , 1325-1340.		0
56	Moderate Alcohol Consumption IsÂAssociated With Lower Risk for HeartÂFailure But Not Atrial Fibrillation. JACC: Heart Failure, 2017, 5, 837-844.	1.9	30
57	Frontal plane T-wave axis orientation predicts coronary events: Findings from the Moli-sani study. Atherosclerosis, 2017, 264, 51-57.	0.4	3
58	High adherence to the Mediterranean diet is associated with cardiovascular protection in higher but not in lower socioeconomic groups: prospective findings from the Moli-sani study. International Journal of Epidemiology, 2017, 46, 1478-1487.	0.9	51
59	Mean platelet volume is associated with lower risk of overall and non-vascular mortality in a general population. Thrombosis and Haemostasis, 2017, 117, 1129-1140.	1.8	7
60	Polyphenol intake is associated with low-grade inflammation, using a novel data analysis from the Moli-sani study. Thrombosis and Haemostasis, 2016, 115, 344-352.	1.8	91
61	Association of pasta consumption with body mass index and waist-to-hip ratio: results from Moli-sani and INHES studies. Nutrition and Diabetes, 2016, 6, e218-e218.	1.5	22
62	A score of low-grade inflammation and risk of mortality: prospective findings from the Moli-sani study. Haematologica, 2016, 101, 1434-1441.	1.7	97
63	Effects of moderate beer consumption on health and disease: A consensus document. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 443-467.	1.1	196
64	Age-sex–specific ranges of platelet count and all-cause mortality: prospective findings from the MOLI-SANI study. Blood, 2016, 127, 1614-1616.	0.6	33
65	Nut consumption is inversely associated with both cancer and total mortality in a Mediterranean population: prospective results from the Moli-sani study. British Journal of Nutrition, 2015, 114, 804-811.	1.2	46
66	T- wave axis deviation is associated with biomarkers of low-grade inflammation. Thrombosis and Haemostasis, 2015, 114, 1199-1206.	1.8	9
67	Orange juice intake during a fatty meal consumption reduces the postprandial low-grade inflammatory response in healthy subjects. Thrombosis Research, 2015, 135, 255-259.	0.8	29
68	Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: results of the 2008–12 National Health Examination Survey. Nephrology Dialysis Transplantation, 2015, 30, 806-814.	0.4	82
69	Postoperative atrial fibrillation and total dietary antioxidant capacity in patients undergoing cardiac surgery: The Polyphemus Observational Study. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 1175-1182.e1.	0.4	24
70	Mediterranean Diet and Low-grade Subclinical Inflammation: The Moli-sani Study. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2015, 15, 18-24.	0.6	47
71	Adherence to the Mediterranean diet is associated with lower platelet and leukocyte counts: results from the Moli-sani study. Blood, 2014, 123, 3037-3044.	0.6	82
72	Both red and blond orange juice intake decreases the procoagulant activity of whole blood in healthy volunteers. Thrombosis Research, 2013, 132, 288-292.	0.8	14

#	Article	IF	CITATIONS
73	Prolonged administration of Ascophyllum nodosum to healthy human volunteers and cardiovascular risk. Nutrafoods, 2013, 12, 137-144.	0.5	5
74	Nutrition knowledge is associated with higher adherence to Mediterranean diet and lower prevalence of obesity. Results from the Moli-sani study. Appetite, 2013, 68, 139-146.	1.8	128
75	Heritability, genetic correlation and linkageÂto the 9p21.3 region of mixed platelet–leukocyte conjugates in families with and without early myocardial infarction. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 684-692.	1.1	9
76	Relation between pulmonary function and 10-year risk for cardiovascular disease among healthy men and women in Italy: the Moli-sani Project. European Journal of Preventive Cardiology, 2013, 20, 862-871.	0.8	25
77	Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. Journal of Thrombosis and Haemostasis, 2013, 11, 1183-1189.	1.9	398
78	Age- And Sex-Related Variations in Platelet Count in Italy: A Proposal of Reference Ranges Based on 40987 Subjects' Data. PLoS ONE, 2013, 8, e54289.	1.1	190
79	Platelet-leukocyte interactions in thrombosis. Thrombosis Research, 2012, 129, 263-266.	0.8	128
80	Total dietary antioxidant capacity and lung function in an Italian population: a favorable role in premenopausal/never smoker women. European Journal of Clinical Nutrition, 2012, 66, 61-68.	1.3	30
81	Platelet proteome in healthy volunteers who smoke. Platelets, 2012, 23, 91-105.	1.1	22
82	Typical breakfast food consumption and risk factors for cardiovascular disease in a large sample of Italian adults. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 347-354.	1.1	40
83	Variability of Platelet Indices and Function: Acquired and Genetic Factors. Handbook of Experimental Pharmacology, 2012, , 395-434.	0.9	14
84	The Moli-sani project: computerized ECG database in a population-based cohort study. Journal of Electrocardiology, 2012, 45, 684-689.	0.4	5
85	Postprandial cell inflammatory response to a standardised fatty meal in subjects at different degree of cardiovascular risk. Thrombosis and Haemostasis, 2012, 107, 530-537.	1.8	17
86	Four-week ingestion of blood orange juice results in measurable anthocyanin urinary levels but does not affect cellular markers related to cardiovascular risk: a randomized cross-over study in healthy volunteers. European Journal of Nutrition, 2012, 51, 541-548.	1.8	30
87	White blood cell count, sex and age are major determinants of heterogeneity of platelet indices in an adult general population: results from the MOLI-SANI project. Haematologica, 2011, 96, 1180-1188.	1.7	151
88	The (+)-enantiomer is responsible for the antiplatelet and anti-inflammatory activity of (±)-indobufen. Journal of Pharmacy and Pharmacology, 2011, 42, 885-887.	1.2	21
89	Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin. Platelets, 2011, 22, 179-187.	1.1	22
90	Epoprostenol inhibits human platelet-leukocyte mixed conjugate and platelet microparticle formation in whole blood. Thrombosis Research, 2011, 128, 446-451.	0.8	30

#	Article	IF	CITATIONS
91	Genetic regulation of inflammation-mediated activation of haemostasis: Family-based approaches in population studies. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 857-861.	1.1	5
92	OFFgelâ€based multidimensional LCâ€MS/MS approach to the cataloguing of the human platelet proteome for an interactomic profile. Electrophoresis, 2011, 32, 686-695.	1.3	28
93	Effects of resveratrol and other wine polyphenols on vascular function: an update. Journal of Nutritional Biochemistry, 2011, 22, 201-211.	1.9	144
94	PLATELET-LEUKOCYTE INTERACTIONS : MULTIPLE LINKS BETWEEN INFLAMMATION , BLOOD COAGULATION AND VASCULAR RISK. Mediterranean Journal of Hematology and Infectious Diseases, 2010, 2, e2010023.	0.5	50
95	Dietary patterns, cardiovascular risk factors and C-reactive protein in a healthy Italian population. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 697-706.	1.1	136
96	Platelet-leukocyte mixed conjugates in patients with atrial fibrillation. Platelets, 2009, 20, 235-241.	1.1	17
97	Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cyclooxygenase-1 level Functional and modelling studies. Thrombosis and Haemostasis, 2009, 102, 336-346.	1.8	63
98	Adherence to Mediterranean diet and anthropometric and metabolic parameters in an observational study in the †Alto Molise' region: The MOLI-SAL project. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 415-421.	1.1	43
99	Current concepts about inhibition of platelet aggregation. Platelets, 2008, 19, 565-570.	1.1	11
100	Application of 2-dimensional difference gel electrophoresis (2D-DIGE) to the study of thrombin-activated human platelet secretome. Platelets, 2008, 19, 43-50.	1.1	46
101	Inhibition by soya isoflavones of human polymorphonuclear leukocyte function: possible relevance for the beneficial effects of soya intake. British Journal of Nutrition, 2008, 99, 240-247.	1.2	11
102	Rebuttal to "Aspirin response variability assessed with the PFA-100 device" by Reny et al Thrombosis and Haemostasis, 2008, 99, 969-969.	1.8	39
103	Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. Thrombosis and Haemostasis, 2008, 99, 14-26.	1.8	116
104	PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A meta-analysis of 19 studies comprising 3,003 patients. Thrombosis and Haemostasis, 2008, 99, 1129-1131.	1.8	50
105	Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: Preliminary in-vitro findings. Thrombosis and Haemostasis, 2007, 97, 1054-1056.	1.8	8
106	Determinants of platelet conjugate formation with polymorphonuclear leukocytes or monocytes in whole blood. Thrombosis and Haemostasis, 2007, 98, 1276-1284.	1.8	30
107	Parnaparin, a low-molecular-weight heparin, prevents P-selectindependent formation of platelet-leukocyte aggregates in human whole blood. Thrombosis and Haemostasis, 2007, 97, 965-973.	1.8	32
108	Platelet function, antiplatelet therapy and clinical outcomes: to test or not to test?. Journal of Thrombosis and Haemostasis, 2007, 5, 1835-1838.	1.9	13

#	Article	IF	CITATIONS
109	Formation of mixed platelet-PMN leukocyte aggregates in the platelet function analyzer (PFA-100) device. Thrombosis and Haemostasis, 2007, 97, 156-157.	1.8	8
110	Formation of mixed platelet-PMN leukocyte aggregates in the platelet function analyzer (PFA-100) device. Thrombosis and Haemostasis, 2007, 97, 156-7.	1.8	1
111	Determinants of platelet conjugate formation with polymorphonuclear leukocytes or monocytes in whole blood. Thrombosis and Haemostasis, 2007, 98, 1276-84.	1.8	15
112	Neutrophils and sepsis. Lancet, The, 2006, 368, 1153.	6.3	3
113	Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. Thrombosis and Haemostasis, 2006, 96, 767-773.	1.8	45
114	Src-family kinases mediate an outside-in signal necessary for β2 integrins to achieve full activation and sustain firm adhesion of polymorphonuclear leucocytes tethered on E-selectin. Biochemical Journal, 2006, 396, 89-98.	1.7	49
115	Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation1. Journal of Thrombosis and Haemostasis, 2006, 4, 1323-1330.	1.9	169
116	Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?. Journal of Thrombosis and Haemostasis, 2006, 4, 2593-2598.	1.9	75
117	The lipoxygenase–cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit. European Journal of Pharmacology, 2006, 546, 95-101.	1.7	8
118	Upregulation of Tissue Factor in Polymorphonuclear Leukocytes from Patients with Myeloproliferative Disorders and Inhibition by Hydroxyurea Treatment Blood, 2006, 108, 1469-1469.	0.6	11
119	More on: tissue factor in neutrophils. Journal of Thrombosis and Haemostasis, 2005, 3, 1114-1114.	1.9	2
120	Aspirin resistance: position paper of the Working Group on Aspirin Resistance. Journal of Thrombosis and Haemostasis, 2005, 3, 1309-1311.	1.9	315
121	Prevention of platelet-polymorphonuclear leukocyte interactions: new clues to the antithrombotic properties of parnaparin, a low molecular weight heparin. Haematologica, 2005, 90, 833-9.	1.7	23
122	Aspirin. Journal of Thrombosis and Haemostasis, 2004, 2, 335-336.	1.9	6
123	Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation. European Journal of Pharmacology, 2004, 488, 79-83.	1.7	23
124	SRC-dependent outside-in signalling is a key step in the process of autoregulation of beta2 integrins in polymorphonuclear cells. Biochemical Journal, 2004, 380, 57-65.	1.7	38
125	Synthesis and Antiaggregant Properties of Stabilized Analogues of Polyunsaturated Fatty Acid Metabolites ChemInform, 2003, 34, no.	0.1	0
126	TxA2-mediated myocardial ischemia as a consequence of an acute lung inflammatory reaction in the rabbit. Journal of Thrombosis and Haemostasis, 2003, 1, 314-319.	1.9	5

#	Article	IF	CITATIONS
127	Aspirin resistance: a revival of platelet aggregation tests?. Journal of Thrombosis and Haemostasis, 2003, 1, 2048-2050.	1.9	61
128	Pharmacokinetic and Pharmacodynamic Differences Between Two Low Dosages of Aspirin May Affect Therapeutic Outcomes. Clinical Pharmacokinetics, 2003, 42, 1059-1070.	1.6	62
129	The epidemiological night where all patients are black: will pharmacogenetics shed some light?. Thrombosis Research, 2003, 112, 273-274.	0.8	6
130	Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. Trends in Pharmacological Sciences, 2003, 24, 245-252.	4.0	114
131	Platelet adhesion and aggregation and fibrin formation in flowing blood: a historical contribution by Giulio Bizzozero. Platelets, 2002, 13, 85-89.	1.1	21
132	How old is Helicobacter pylori?. Lancet, The, 2002, 359, 1700-1701.	6.3	1
133	Inhibition of cGMP-dependent protein kinases potently decreases neutrophil spontaneous apoptosis. Biochemical and Biophysical Research Communications, 2002, 297, 498-501.	1.0	22
134	Licofelone, a dual lipoxygenase–cyclooxygenase inhibitor, downregulates polymorphonuclear leukocyte and platelet function. European Journal of Pharmacology, 2002, 453, 131-139.	1.7	27
135	Synthesis and antiaggregant properties of Stabilized analogues of polyunsaturated fatty acid metabolites. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2511-2514.	1.0	4
136	Synthesis and antiaggregant properties of new analogues of polyunsaturated fatty acid metabolites with naphthalene or quinoline cores. Tetrahedron Letters, 2002, 43, 5221-5223.	0.7	4
137	Platelet–leukocyte interactions relevant to vascular damage and thrombosis. , 2002, , 412-431.		2
138	Pharmacogenetics as a new antiplatelet strategy. , 2002, , 964-977.		4
139	Ischemic heart disease: the platelet paradox. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2002, 3 Suppl 4, 5S-8S.	0.1	1
140	Platelet/polymorphonuclear leukocyte adhesion: a new role for SRC kinases in Mac-1 adhesive function triggered by P-selectin. Blood, 2001, 98, 108-116.	0.6	90
141	Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood, 2000, 96, 4261-4266.	0.6	259
142	Polymorphonuclear Leukocyte Apoptosis Is Inhibited by Platelet-released Mediators, Role of TGFÎ2-1. Thrombosis and Haemostasis, 2000, 84, 478-483.	1.8	43
143	Platelet Contribution to Leukotriene Production in Inflammation: In Vivo Evidence in the Rabbit. Thrombosis and Haemostasis, 1999, 81, 442-448.	1.8	39
144	P-Selectin-β2-Integrin Cross-Talk: A Molecular Mechanism For Polymorphonuclear Leukocyte Recruitment At The Site Of Vascular Damage. Thrombosis and Haemostasis, 1999, 82, 787-793.	1.8	65

#	Article	IF	CITATIONS
145	Platelet/Polymorphonuclear Leukocyte Interaction: P-Selectin Triggers Protein-Tyrosine Phosphorylation–Dependent CD11b/CD18 Adhesion: Role of PSGL-1 as a Signaling Molecule. Blood, 1999, 93, 876-885.	0.6	313
146	Recent Advances in Platelet-Polymorphonuclear Leukocyte Interaction. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1999, 29, 41-49.	0.5	39
147	Platelet/Polymorphonuclear Leukocyte Interaction: P-Selectin Triggers Protein-Tyrosine Phosphorylation–Dependent CD11b/CD18 Adhesion: Role of PSGL-1 as a Signaling Molecule. Blood, 1999, 93, 876-885.	0.6	9
148	Kinetic Evaluation of Endogenous Leukotriene B4 Ande4 Acute Activation of Inflammatory Cells in the Rabbit. Advances in Experimental Medicine and Biology, 1999, 469, 437-441.	0.8	0
149	Effect of trans -resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. British Journal of Pharmacology, 1998, 123, 1691-1699.	2.7	212
150	Kinetics of Endogenous Leukotriene B4 and E4 Production Following Injection of the Chemotactic Peptide FMLP in the Rabbit. Prostaglandins, 1997, 54, 699-711.	1.2	4
151	N-ω-Carbethoxypentyl-4-quinolones: A New Class of Leukotriene Biosynthesis Inhibitors. Archiv Der Pharmazie, 1997, 330, 100-106.	2.1	3
152	Enhanced Response to Chemotactic Activation of Polymorphonuclear Leukocytes from Patients with Heart Valve Replacement. Thrombosis and Haemostasis, 1997, 77, 071-074.	1.8	4
153	Different Requirement of Intracellular Calcium and Protein Kinase C for Arachidonic Acid Release and Serotonin Secretion in Cathepsin G-activated Platelets. Thrombosis and Haemostasis, 1997, 78, 919-925.	1.8	17
154	Platelet-Polymorphonuclear Leukocyte Functional Interactions: Role Of Adhesive Molecules. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 20-27.	0.5	0
155	Thrombin-activated Human Platelets Release two NAP-2 Variants that Stimulate Polymorphonuclear Leukocytes. Thrombosis and Haemostasis, 1996, 76, 780-785.	1.8	66
156	Red Wine, Aspirin and Platelet Function. Thrombosis and Haemostasis, 1996, 76, 818-819.	1.8	21
157	The endoperoxides/TxA2 analogue, U46619, inhibits human polymorphonuclear leukocyte function. Journal of Leukocyte Biology, 1995, 57, 72-79.	1.5	2
158	Proteolysis of the Human Platelet and Endothelial Cell Thrombin Receptor by Neutrophil-derived Cathepsin G. Journal of Biological Chemistry, 1995, 270, 11168-11175.	1.6	140
159	Platelet-released NAP-2 variants induce PMN leukocyte intracellular calcium changes ([Ca2+]i). Pharmacological Research, 1995, 31, 306.	3.1	0
160	Platelet Activation by Polymorphonuclear Leukocytes: Role of Cathepsin G and P-Selectin. Thrombosis and Haemostasis, 1995, 74, 218-223.	1.8	44
161	Interaction Between Glycosaminoglycans, Platelets, and Leukocytes. Seminars in Thrombosis and Hemostasis, 1994, 20, 245-253.	1.5	18
162	Simultaneous determination of leukotrienes B4 and E4 in whole blood and of leukotriene E4 in urine of rabbit by reversed-phase high-performance liquid chromatography. Biomedical Applications, 1994, 658, 261-269.	1.7	17

#	Article	IF	CITATIONS
163	Polymorphonuclear Leukocyte-Platelet Interaction: Role of P-Selectin in Thromboxane B2 and Leukotriene C4 Cooperative Synthesis. Thrombosis and Haemostasis, 1994, 72, 450-456.	1.8	98
164	Effects of glycosaminoglycans on platelet and leucocyte function: Role of N-sulfation. Biochemical Pharmacology, 1993, 46, 958-960.	2.0	22
165	Antiplatelet activity of 2-(6-carboxyhexyl)-3-n-hexylcyclohexylamine (IBI P-05006), a thromboxane receptor antagonist. European Journal of Pharmacology, 1993, 232, 41-45.	1.7	1
166	Polymorphonuclear leucocyte-dependent modulation of platelet function: Relevance to the pathogenesis of thrombosis. Pharmacological Research, 1992, 26, 261-268.	3.1	18
167	Inhibition by heparin of platelet activation induced by neutrophil-derived cathepsin G. European Journal of Pharmacology, 1992, 216, 401-405.	1.7	33
168	Defibrotide Inhibits Platelet Activation by Cathepsin G Released From Stimulated Polymorphonuclear Leukocytes. Thrombosis and Haemostasis, 1992, 67, 660-664.	1.8	22
169	Pathophysiology of Critical Leg Ischaemia and Mode of Action of Prostaglandins. , 1992, 37, 18-26.		0
170	Mechanism of Action and Clinical Use of Prostanoids. , 1990, , 117-137.		11
171	Animal experiments and recent progress in thrombosis research. , 1990, , 97-109.		0
172	Moderate anticoagulation by salicylate prevents thrombosis without bleeding complications. Biochemical Pharmacology, 1988, 37, 4743-4745.	2.0	6
173	Prolongation of bleeding time by aspirin: A dual mechanism?. Thrombosis Research, 1988, 50, 907-912.	0.8	6
174	A new model of pulmunary microembolism in the mouse. Journal of Pharmacological Methods, 1988, 20, 161-167.	0.7	11
175	Pharmacokinetics of enteric-coated aspirin and inhibition of platelet thromboxane A2 and vascular prostacyclin generation in humans. Clinical Pharmacology and Therapeutics, 1987, 42, 175-180.	2.3	17
176	Requirement of ADP for arachidonic acid-induced platelet aggregation: studies with selective thromboxane-synthase inhibitors. Biochemical Pharmacology, 1986, 35, 1201-1203.	2.0	9
177	Low dose aspirin does not prevent fibrinolytic response to venous occlusion. Biochemical Pharmacology, 1986, 35, 3147-3150.	2.0	27
178	Current Issues in Thrombosis Prevention with Antiplatelet Drugs. Drugs, 1986, 31, 517-549.	4.9	32
179	Effects of 1 gram oral or intravenous aspirin on urinary excretion of thromboxane B2 and 6-keto-PGF1α in healthy subjects. Prostaglandins, 1986, 32, 691-701.	1.2	9
180	Inhibition of Platelet Thromboxane Generation by Suloctidil in Man. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1986, 16, 362-368.	0.5	1

#	Article	IF	CITATIONS
181	Salicylate may prevent the inhibitory effect of indomethacin on serum thromboxane formation in man. Prostaglandins, Leukotrienes, and Medicine, 1986, 21, 111-112.	0.8	3
182	Contribution of ADP to the amplification of primary platelet aggregation by platelet activating factor (PAF): modulatory role of aspirin. Agents and Actions, 1986, 17, 506-511.	0.7	4
183	Differential Salicylate-Aspirin Interaction on Vascular Prostacyclin and Platelet Thromboxane Synthesis in Patients Undergoing Saphenectomy. Experimental Biology and Medicine, 1985, 180, 533-537.	1.1	6
184	Prostaglandins and human platelet aggregation. Biochemical Pharmacology, 1985, 34, 307-310.	2.0	13
185	Inhibition of human platelet thromboxane generation by aspirin in the absence of measurable drug levels in peripheral blood. Biochemical Pharmacology, 1985, 34, 1839-1841.	2.0	21
186	Inhibition of human platelet cyclo-oxygenase activity by sulfinpyrazone and three of its metabolites. European Journal of Pharmacology, 1984, 101, 209-214.	1.7	16
187	SQ 22536, an Adenylate-Cyclase Inhibitor, Prevents the Antiplatelet Effect of Dazoxiben, a Thromboxane-Synthetase Inhibitor. Thrombosis and Haemostasis, 1984, 51, 125-128.	1.8	19
188	Salicylate fails to prevent the inhibitory effect of 5,8,11,14-eicosatetraynoic acid on human platelet cyclo-oxygenase and lipoxygenase activities. Biochimica Et Biophysica Acta - General Subjects, 1983, 759, 125-127.	1.1	18
189	Interaction of salicylate and other non-steroidal anti-inflammatory drugs with aspirin on platelet and vascular cyclo-oxygenase activity. Thrombosis Research, 1983, 29, 153-159.	0.8	8
190	PHARMACOLOGY OF ANTIPLATELET DRUGS AND CLINICAL TRIALS ON THROMBOSIS PREVENTION: A DIFFICULT LINK. Lancet, The, 1982, 320, 974-977.	6.3	51
191	ASPIRIN INHIBITS PLATELET AGGREGATION BUT NOT BECAUSE IT PREVENTS THROMBOXANE SYNTHESIS. Lancet, The, 1982, 320, 775.	6.3	8
192	Arachidonic acid induces human platelet-fibrin retraction: The role of platelet cyclic endoperoxides. Thrombosis Research, 1982, 25, 299-306.	0.8	3
193	Thromboxane Synthetase Inhibition Results in Increased Platelet Sensitivity to Prostacyclin. Thrombosis and Haemostasis, 1982, 47, 294-294.	1.8	17
194	Sulphinpyrazone prevents in vivo the inhibitory effect of aspirin on rat platelet cyclo-oxygenase activity. Biochemical Pharmacology, 1981, 30, 2773-2776.	2.0	10
195	Impaired Thromboxane Production by Newly Formed Platelets after Aspirin Administration to Thrombocytopenic Rats. British Journal of Haematology, 1980, 46, 465-469.	1.2	23
196	PROSTACYCLIN OVERPRODUCTION IN BARTTER'S SYNDROME. Lancet, The, 1979, 314, 767-769.	6.3	64
197	SUBCELLULAR DISTRIBUTION OF ETORPHINE IN RAT BRAIN AND EVIDENCE FOR <i>in vivo</i> STEREOSPECIFIC BINDING. British Journal of Pharmacology, 1978, 62, 31-38.	2.7	10
198	Effect of anticholinergic drugs on gastro-intestinal absorption of L-DOPA in rats and in man. European Journal of Pharmacology, 1976, 35, 293-299.	1.7	21

#	Article	IF	CITATIONS
199	Chronic morphine administration: Plasma levels and withdrawal syndrome in rats. Pharmacology Biochemistry and Behavior, 1976, 4, 323-327.	1.3	36
200	3H-reserpine persistently bound "in vivo―to rat brain subcellular components: Limited removal by peanut oil extraction. Life Sciences, 1974, 14, 2267-2276.	2.0	12
201	Effects of l-dopa administration on the serotonergic system in rat brain: Correlation between levels of l-dopa accumulated in the brain and depletion of serotonin and tryptophan. European Journal of Pharmacology, 1974, 27, 191-197.	1.7	32